GC-LTFU-001

Inclusion Criteria:

* Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
* Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.

Exclusion Criteria:

Not Applicable

Other protocol-defined inclusion/exclusion criteria apply

Multiple Myeloma

Indiana University (IU)

• Indiana University Hospital / IU Simon Cancer Center

• Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
  Abramson JS;Palomba ML;Gordon LI;Lunning MA;Wang ML;Arnason JE;Purev E;Maloney DG;Andreadis CB;Sehgal A;Solomon SR;Ghosh N;Dehner C;Kim Y;Ogasawara K;Kostic A;Siddiqi T;